Macular neovascularization secondary to age-related macular degeneration (nAMD)
Conditions
Brief summary
Mean change from baseline in BCVA ETDRS letter score at Week 52
Detailed description
Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104, Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104, Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm, Time to first aflibercept injection after Week 4 in the 4D-150 arm, Mean change from baseline in CST over time through Weeks 52 and 104, Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104
Interventions
Sponsors
4d Molecular Therapeutics Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in BCVA ETDRS letter score at Week 52 | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104, Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104, Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm, Time to first aflibercept injection after Week 4 in the 4D-150 arm, Mean change from baseline in CST over time through Weeks 52 and 104, Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104 | — |
Countries
Bulgaria, France, Germany, Hungary, Italy, Latvia, Lithuania, Portugal, Spain
Outcome results
None listed